Overview:

• Supports healthy androgenic system.

• Supports natural defense against negative effects of androgens.

• Protects androgen receptor levels.

Duration:

24 hours

​

Ingredients:

Propylene glycol, 2-(Methoxycarbonyl) aniline (50mg per ml), sucralose and bioactive flavours.

Application:

1ml daily with food in the morning.

Legal Status:

Legal in Australia, food additive FEMA

 

Description:

2-(Methoxycarbonyl)aniline (M-5862) is a natural aryl hydrocarbon which supports healthy androgen receptor activity.

 

Application of 2-(Methoxycarbonyl)aniline has demonstrated support of healthy androgen receptor activity without down regulation of the total receptor expression (10)

1) Roell, D., Rösler, T. W., Degen, S., Matusch, R., & Baniahmad, A. (2011). Antiandrogenic activity of anthranilic acid ester derivatives as novel
lead structures to inhibit prostate cancer cell proliferation. Chemical biology & drug design, 77(6), 450-459.
2) Negro-Vilar, A. (1999). Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. The
Journal of Clinical Endocrinology & Metabolism, 84(10), 3459-3462.
3) Yin, D., Gao, W., Kearbey, J. D., Xu, H., Chung, K., He, Y., ... & Dalton, J. T. (2003). Pharmacodynamics of selective androgen receptor
modulators. Journal of Pharmacology and Experimental Therapeutics, 304(3), 1334-1340.
4) https://tga-search.clients.funnelback.com/s/search.html?query=&collection=tga-artg
5) Gill, A. (2017). Standard for the uniform scheduling of medicines and poisons: The Poisons Standard 2017. Australian
Government–Department of health and aging: Therapeutic Goods Administration, Canberra.
6) Nickols, N. G., & Dervan, P. B. (2007). Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding
polyamide. Proceedings of the National Academy of Sciences, 104(25), 10418-10423.
7) Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., & Balk, S. P. (2002). Bicalutamide functions as an androgen receptor antagonist by assembly of
a transcriptionally inactive receptor. Journal of Biological Chemistry, 277(29), 26321-26326.
8) Sieber, P. R., Keiller, D. L., Kahnoski, R. J., Gallo, J., & Mcfadden, S. (2004). Bicalutamide 150 mg maintains bone mineral density during
monotherapy for localized or locally advanced prostate cancer. The Journal of urology, 171(6), 2272-2276.
9) Schellhammer, P. F. (2002). An evaluation of bicalutamide in the treatment of prostate cancer. Expert opinion on pharmacotherapy, 3(9),
1313-1328.
10) Roell, D., Rösler, T. W., Degen, S., Matusch, R., & Baniahmad, A. (2011). Antiandrogenic activity of anthranilic acid ester derivatives as novel
lead structures to inhibit prostate cancer cell proliferation. Chemical biology & drug design, 77(6), 450-459.